Pharmaceutical News

RSS

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

...

9 Sep 2013

PMSI, Progressive Medical collaborate to deliver comprehensive workers' compensation pharmacy benefit management services

Progressive Medical and PMSI announced today that the two companies have entered into a definitive agreement to merge. The transaction is expected to close in the fourth quarter subject to receipt of regulatory clearance. The combined company, which will be led by Executive Chairman Eileen Auen from PMSI and Co-CEOs Emry Sisson and Tommy Young from Progressive Medical, will deliver comprehensive workers' compensation pharmacy benefit management services including end-to-end pharmacy, ancillary and settlement solutions.

7 Sep 2013

McNeil Recalls 200,000 bottles of Concentrated MOTRIN Infants Drops Original Berry Flavor 1/2 fl oz

McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. ("McNeil") is voluntarily recalling at the retail level three lots, approximately 200,000 bottles, of Concentrated MOTRIN® Infants' Drops Original Berry Flavor 1/2 fl oz bottles distributed in the United States.

7 Sep 2013

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

7 Sep 2013

Altaire Pharmaceuticals recalls 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution

Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling a total of nine (9) lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution, 30 mL, to the consumer level. There have been no reports of adverse effects to consumers so far.

7 Sep 2013

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

Medivir discontinues development of hepatitis B compound MIV-210 on collaboration with Daewoong

Medivir AB today announced that it has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Daewoong Pharmaceutical Co. Ltd.,.

7 Sep 2013

New flexible microneedle patch allows drugs to deliver directly through skin

An assistant professor with the Virginia Tech - Wake Forest School of Biomedical Engineering has developed a flexible microneedle patch that allows drugs to be delivered directly and fully through the skin. The new patch can quicken drug delivery time while cutting waste, and can likely minimize side-effects in some cases, notable in vaccinations and cancer therapy.

7 Sep 2013

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

...

6 Sep 2013

FDA schedules meeting on 3 October to discuss QRxPharma's MOXDUO NDA for acute pain

QRxPharma Limited announced today the United States Food and Drug Administration has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application for the treatment of moderate to severe acute pain.

6 Sep 2013

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

...

6 Sep 2013

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

...

6 Sep 2013

Medivir, Daewoong Discontinue HBV Drug Development

...

6 Sep 2013

Short-term blood sugar control in diabetes patients has limited effect on risk of cardiovascular problems

An international study has shown that short-term blood sugar control in patients with diabetes has a limited effect on their risk of cardiovascular problems, such as heart disease and stroke.

6 Sep 2013

Researchers explore distinctions between natural sleep and anesthetic unconsciousness

Falling asleep in your bed at night and being "put to sleep" under general anesthesia - as well as waking up in the morning or coming out of anesthesia - aren't quite the same thing, yet they share some important similarities. Max Kelz, MD, PhD, assistant professor of Anesthesiology and Critical Care at the Perelman School of Medicine at the University of Pennsylvania, along with colleagues from Penn, UCSD, Howard Hughes Medical Institute, and Thomas Jefferson University, explored the distinctions between anesthetic unconsciousness and sleep by manipulating the genetic pathways known to be involved in natural sleep and studying the resulting effects on anesthetic states.

6 Sep 2013

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.

6 Sep 2013

Osteoporosis drug could provide effective pain relief to patients with osteoarthritis

St George's, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.

6 Sep 2013

Endo Pharmaceuticals' complete response submission to AVEED NDA accepted by FDA

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has accepted for review the complete response submission made by Endo to the new drug application for its long-acting testosterone undecanoate injection, AVEED, intended for men diagnosed with hypogonadism.

6 Sep 2013

Pharmaceutical News

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

PMSI, Progressive Medical collaborate to deliver comprehensive workers' compensation pharmacy benefit management services

McNeil Recalls 200,000 bottles of Concentrated MOTRIN Infants Drops Original Berry Flavor 1/2 fl oz

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Altaire Pharmaceuticals recalls 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Medivir discontinues development of hepatitis B compound MIV-210 on collaboration with Daewoong

New flexible microneedle patch allows drugs to deliver directly through skin

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

FDA schedules meeting on 3 October to discuss QRxPharma's MOXDUO NDA for acute pain

Sanofi To Commercialize Pozen Proton Pump Inhibitor/Aspirin Product

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

Medivir, Daewoong Discontinue HBV Drug Development

Short-term blood sugar control in diabetes patients has limited effect on risk of cardiovascular problems

Researchers explore distinctions between natural sleep and anesthetic unconsciousness

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Osteoporosis drug could provide effective pain relief to patients with osteoarthritis

Endo Pharmaceuticals' complete response submission to AVEED NDA accepted by FDA

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News